Ameriprise’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-55,782
| Closed | -$2.88M | – | 4111 |
|
|
2022
Q3 | $2.88M | Buy |
55,782
+46,615
| +509% | +$1.93M | ﹤0.01% | 2597 |
|
|
2022
Q2 | $227K | Buy |
+9,167
| New | +$202K | ﹤0.01% | 3654 |
|
|
2021
Q2 | – | Sell |
-32,577
| Closed | -$1.67M | – | 4000 |
|
|
2021
Q1 | $1.67M | Buy |
32,577
+16,150
| +98% | +$972K | ﹤0.01% | 2929 |
|
|
2020
Q4 | $1.02M | Buy |
16,427
+1,485
| +10% | +$85K | ﹤0.01% | 3079 |
|
|
2020
Q3 | $819K | Buy |
+14,942
| New | +$804K | ﹤0.01% | 3055 |
|
|
2019
Q3 | – | Sell |
-111,227
| Closed | -$1.03M | – | 3794 |
|
|
2019
Q2 | $1.03M | Sell |
111,227
-150,169
| -57% | -$1.74M | ﹤0.01% | 3053 |
|
|
2019
Q1 | $3.63M | Sell |
261,396
-3,100
| -1% | -$35.5K | ﹤0.01% | 2427 |
|
|
2018
Q4 | $2.89M | Buy |
264,496
+130,109
| +97% | +$1.37M | ﹤0.01% | 2475 |
|
|
2018
Q3 | $1.7M | Buy |
134,387
+64,066
| +91% | +$772K | ﹤0.01% | 2870 |
|
|
2018
Q2 | $926K | Buy |
+70,321
| New | +$841K | ﹤0.01% | 3044 |
|
|
2014
Q4 | – | Sell |
-610
| Closed | -$3K | – | 4571 |
|
|
2014
Q3 | $3K | Buy |
610
+580
| +1,933% | +$3.07K | ﹤0.01% | 5313 |
|
|
2014
Q2 | $0 | Buy |
+30
| New | +$168 | ﹤0.01% | 5682 |
|
|
2013
Q4 | – | Sell |
-1,532
| Closed | -$9K | – | 5478 |
|
|
2013
Q3 | $9K | Hold |
1,532
| – | – | ﹤0.01% | 4986 |
|
|
2013
Q2 | $22K | Buy |
+1,532
| New | +$19.9K | ﹤0.01% | 4214 |
|
Other funds holding CCXI
Ameriprise's CCXI Position: Q4 2022 in Review
Ameriprise sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 55,782 shares — an estimated $2.88M sold.
Ameriprise first reported a position in CCXI in Q2 2013 and held it in 14 quarters. The position peaked at $3.63M in Q1 2019. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Ameriprise reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Ameriprise sold 55,782 ChemoCentryx, Inc. shares in Q4 2022, an estimated $2.88M.
- Ameriprise first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 14 quarters.
- Ameriprise's ChemoCentryx, Inc. position peaked at $3.63M in Q1 2019.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Ameriprise's 13F filing for Q4 2022, filed 14 Feb 2023.